Oxfordbiotherapeutics
Oxford Biotherapeutics is seeking a Scientist to lead the discovery and optimization of multi-specific T-cell Engagers (TCEs). The role involves overseeing antibody design and production, executing in vitro functional studies, and generating decision-enabling data from early discovery through IND-enabling studies. This position combines hands-on experimental expertise in immunology with scientific leadership to advance novel antibody therapeutics for cancer treatment.
Headquarters
Oxford, England, United Kingdom
Company Size
11-50 employees
Founded
2004
Oxford BioTherapeutics is a biotechnology company focused on developing first‑in‑class oncology therapies. They pioneer targeted approaches including Antibody‑Drug Conjugates (ADCs), immuno‑oncology agents, T‑Cell Engagers (TCEs), and radiopharmaceuticals. The company advances a pipeline driven by translational science and strategic partnerships to accelerate delivery of novel cancer treatments to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Oxfordbiotherapeutics.
14% above the average for this role
Senior Scientist - Non-Clinical Drug Safety
Digital Biology
Scientist II, In Vitro Pharmacology
AbbVie
Group Leader - Antibody Screening and Pharmacology
Cancer Research UK Jersey
Senior Scientist II (Protein & Antibody Production)
Exelixis
Research (or Senior) Scientist - Antibody Discovery & Optimization
City of Winnipeg
Senior Scientist in Antibody Development
Shennon Biotechnologies Inc.